Drug Profile
PCAR 019
Alternative Names: Anti-CD19 CAR T cells - PersonGen BioTherapeutics; Anti-CD19 CAR-transduced T cells - PersonGen BioTherapeutics; Anti-CD19 chimeric antigen receptor T cell therapy - PersonGen BioTherapeutics; CD19-CART; PCAR019; Targeting hcd19 chimeric antigen receptorLatest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator PersonGen Biotherapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Leukaemia; Lymphoma
- No development reported Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for clinical-Phase-Unknown development in Non-Hodgkin's-lymphoma(Refractory metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
- 28 Feb 2021 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In the elderly, Second-line therapy or greater, In adults) in China (IV, Infusion)
- 01 Oct 2016 PersonGen BioTherapeutics initiates a phase-I/II trial in Lymphoma and Leukaemia (In adults, Second-line therapy or greater) in China (Parenteral) (NCT02819583)